Timothy J Fendler1, John A Spertus2, Kensey L Gosch2, Philip G Jones2, Jared M Bruce2, Michael E Nassif2, Kelsey M Flint2, Shannon M Dunlay2, Larry A Allen2, Suzanne V Arnold2. 1. From the Mid-America Heart Institute, Kansas City, MO (T.J.F., J.A.S., K.L.G., P.G.J., S.V.A.); University of Missouri-Kansas City (T.J.F., J.A.S., J.M.B., S.V.A.); Washington University School of Medicine, Saint Louis, MO (M.E.N.); University of Colorado School of Medicine, Aurora (K.M.F., L.A.A.); and Mayo Clinic of Rochester, MN (S.M.D.). fendlert@umkc.edu. 2. From the Mid-America Heart Institute, Kansas City, MO (T.J.F., J.A.S., K.L.G., P.G.J., S.V.A.); University of Missouri-Kansas City (T.J.F., J.A.S., J.M.B., S.V.A.); Washington University School of Medicine, Saint Louis, MO (M.E.N.); University of Colorado School of Medicine, Aurora (K.M.F., L.A.A.); and Mayo Clinic of Rochester, MN (S.M.D.).
Abstract
BACKGROUND: After left ventricular assist device (LVAD) placement for advanced heart failure, increased cerebral perfusion should result in improved cognitive function. However, stroke (a well-known LVAD complication) and subclinical cerebral ischemia may result in transient or permanent cognitive decline. We sought to describe the incidence and predictors of cognitive decline after LVAD using a valid, sensitive assessment tool. METHODS AND RESULTS: Among 4419 patients in the Interagency Registry for Mechanically Assisted Circulatory Support who underwent LVAD implantation between May 2012 and December 2013, cognitive function was assessed in 1173 patients with the Trail Making B Test before LVAD and at 3, 6, and 12 months. The test detects several forms of cognitive impairment, including subclinical stroke. Cognitive decline was defined as a clinically important increase during follow-up using a moderate Cohen d effect size of 0.5×baseline SD (32 s). The cumulative incidence of cognitive decline in the year after LVAD implantation, treating death and transplantation as competing risks, was 29.2%. In adjusted analysis, older age (≥70 versus <50 years; hazard ratio, 2.24; 95% confidence interval 1.46-3.44; P(trend)<0.001) and destination therapy (hazard ratio, 1.42; 95% confidence interval, 1.05-1.92) were significantly associated with greater risk of cognitive decline. CONCLUSIONS: Cognitive decline occurs commonly in patients in the year after LVAD and is associated with older age and destination therapy. These results could have important implications for patient selection and improved communication of risks before LVAD implantation. Additional studies are needed to explore the association between cognitive decline and subsequent stroke, health status, and mortality in patients after LVAD.
BACKGROUND: After left ventricular assist device (LVAD) placement for advanced heart failure, increased cerebral perfusion should result in improved cognitive function. However, stroke (a well-known LVAD complication) and subclinical cerebral ischemia may result in transient or permanent cognitive decline. We sought to describe the incidence and predictors of cognitive decline after LVAD using a valid, sensitive assessment tool. METHODS AND RESULTS: Among 4419 patients in the Interagency Registry for Mechanically Assisted Circulatory Support who underwent LVAD implantation between May 2012 and December 2013, cognitive function was assessed in 1173 patients with the Trail Making B Test before LVAD and at 3, 6, and 12 months. The test detects several forms of cognitive impairment, including subclinical stroke. Cognitive decline was defined as a clinically important increase during follow-up using a moderate Cohen d effect size of 0.5×baseline SD (32 s). The cumulative incidence of cognitive decline in the year after LVAD implantation, treating death and transplantation as competing risks, was 29.2%. In adjusted analysis, older age (≥70 versus <50 years; hazard ratio, 2.24; 95% confidence interval 1.46-3.44; P(trend)<0.001) and destination therapy (hazard ratio, 1.42; 95% confidence interval, 1.05-1.92) were significantly associated with greater risk of cognitive decline. CONCLUSIONS:Cognitive decline occurs commonly in patients in the year after LVAD and is associated with older age and destination therapy. These results could have important implications for patient selection and improved communication of risks before LVAD implantation. Additional studies are needed to explore the association between cognitive decline and subsequent stroke, health status, and mortality in patients after LVAD.
Authors: M F Newman; J L Kirchner; B Phillips-Bute; V Gaver; H Grocott; R H Jones; D B Mark; J G Reves; J A Blumenthal Journal: N Engl J Med Date: 2001-02-08 Impact factor: 91.245
Authors: Ralph J Petrucci; Karen C Truesdell; Anne Carter; Naomi E Goldstein; Megan M Russell; Danielle Dilkes; Jane M Fitzpatrick; Carole E Thomas; Margaret E Keenan; Lewis A Lazarus; Nancy D Chiaravalloti; Joseph J Trunzo; Johan W Verjans; Elena C Holmes; Louis E Samuels; Jagat Narula Journal: Ann Thorac Surg Date: 2006-05 Impact factor: 4.330
Authors: Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245
Authors: M A Dew; R L Kormos; S Winowich; R C Harris; E A Stanford; L Carozza; B P Griffith Journal: J Heart Lung Transplant Date: 2001-11 Impact factor: 10.247
Authors: Joost Witlox; Lisa S M Eurelings; Jos F M de Jonghe; Kees J Kalisvaart; Piet Eikelenboom; Willem A van Gool Journal: JAMA Date: 2010-07-28 Impact factor: 56.272
Authors: Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier Journal: N Engl J Med Date: 2009-11-17 Impact factor: 91.245
Authors: James K Kirklin; David C Naftel; Robert L Kormos; Lynne W Stevenson; Francis D Pagani; Marissa A Miller; J T Baldwin; J Timothy Baldwin; James B Young Journal: J Heart Lung Transplant Date: 2013-02 Impact factor: 10.247
Authors: C Madl; G Grimm; L Kramer; R Koppensteiner; M Hirschl; W Yeganehfar; M M Hirschl; A Ugurluoglu; B Schneider; H Ehringer Journal: Eur J Clin Invest Date: 1994-08 Impact factor: 4.686
Authors: Marykay A Pavol; Joshua Z Willey; Ying Wei; Melana Yuzefpolskaya; Randolph S Marshall; Philip J Marascalco; Jason Harwood; Ronald M Lazar Journal: Gen Thorac Cardiovasc Surg Date: 2018-05-23
Authors: Evgenij V Potapov; Christiaan Antonides; Maria G Crespo-Leiro; Alain Combes; Gloria Färber; Margaret M Hannan; Marian Kukucka; Nicolaas de Jonge; Antonio Loforte; Lars H Lund; Paul Mohacsi; Michiel Morshuis; Ivan Netuka; Mustafa Özbaran; Federico Pappalardo; Anna Mara Scandroglio; Martin Schweiger; Steven Tsui; Daniel Zimpfer; Finn Gustafsson Journal: Eur J Cardiothorac Surg Date: 2019-08-01 Impact factor: 4.191
Authors: Cecilia Maria Veraar; Harald Rinösl; Karina Kühn; Keso Skhirtladze-Dworschak; Alessia Felli; Mohamed Mouhieddine; Johannes Menger; Ekaterina Pataraia; Hendrik Jan Ankersmit; Martin Dworschak Journal: Crit Care Date: 2019-12-30 Impact factor: 9.097